Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Investor Presentation (March 2019)
25 slides from Sanuwave Health's investor presentation, Mar 5, 2019
Slide 1: SANUWAVE: Healing today. Curing tomorrow.
SANUVAVE Healing today. Curing tomorrow. Creating a brighter future by providing novel and cost effective solutions, focused on societal needs with the sole purpose of bettering lives everywhere OTCQB: March 2019
Slide 2: Forward-Looking Statement Disclaimer
Forward-Looking Statement Disclaimer This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective.
Slide 3: SANUWAVE Health
SANUWAVE Health SANUWAVE Health (SNWV), Inc. is an emerging shockwave technology company focused on the -_ dennePaAce development and commercialization of patented noninvasive, high-energy, acoustic focused, shockwaves for the repair and regeneration of tissue, musculoskeletal and vascular structure
Slide 4: Investment Highlights & Recent Developments
Investment Highlights & Recent Developments..." Accomplishments in 2018 Goals for 2019 * Hired Shri Parikh, President Healthcare 100 US Placements ; 300 certified users * Received reimbursement tracking for DFU procedure Reimbursement; finish with at least 10 million * Signed Premier Shockwave as th
Slide 5: A Leader in Shockwave Technology
A Leader in Shockwave Technology Development and Commercialization Patented, non-invasive devices for the repair and regeneration of: * Skin * Musculoskeletal tissue + Vascular structures Devices activate biologic signaling and angiogenic responses, producing: * New vascularization * Microcirculator
Slide 6: Global Wound Care Market Overview
EE The increasing prevalence of chronic wounds is being driven by the sharp rise in diabetes and obesity SANUWAVE lobal Wound Care Market Overview US and worldwide wound prevalence Types of wound Surgical wounds Traumatc wounds Lacerations Burn wounds Burn wounds Burn wounds P Venous ulcers Diabetic
Slide 7: U.S. Wound Care Market Overview - Prevalence of wounds
U.S. Wound Care Market Overview - Prevalence of wounds US prevalence of all wounds U.S. prevalence of hard-to-heal wounds* (8 million pa) (3.2 million pa) Diabetic foot ve uber Diabetic foot ra 18% Venous ulcer uker 15% 29% Asteria Ulcer 3% ~~ Arterial Ulcer Trauma/ 8% surgical sd ‘ Traumal Bums sag
Slide 8: The dermaPACE System meets the market need for better outcomes at lower cost
tit 2 The dermaPACE® System meets the market need for better outcomes at lower cost Key Industry Needs ooeo8d8 GO BROADER ACCESS REDUCED COSTS IMPROVED HEALTH BETTER PATIENT TO CARE OUTCOMES CARE EXPERIENCE SANUWAVE LT 8
Slide 9: dermaPACE System positions SANUWAVE for large revenue potential
The dermaPACE® System positions SANUWAVE for large revenue potential across wound indications in the United States SANUWAVE Estimated at >$45 Billion Annual wound Pressure ulcers Diabetic foot ulcers (PUs) ?~$12Bn (DFUs)*~$15Bn Annual treatment Annual treatment costs. Inpatient only, costs. All care
Slide 10: dermaPACE positions for continued success in large and emerging markets
The dermaPACE® Pe varict overs | a System =~ Aging population = Clinical = Reach woe =" Chronic illnesses practice/education * Funding pos itions = Emerging middle * Innovation . Regulatory class environment SAN UWAVE Volume of wounds by geography (M) Value of wounds by geography ($M) for conti n ue
Slide 11: Strategy to Capture Growth Opportunities
Strategy to Capture Growth Opportunities _ Broader Access Reduce Cost & Improve Efficiency Improve Clinical Outcomes and Patient Experience SANUWAVE’ Drive Global Expansion Deliver Economic Value Accelerate Therapy Innovation U.S. launch of dermaPACE Sales coverage ramp up Enhanced commercialization
Slide 12: Market Opportunity with The dermaPACE System
Market Opportunity with The dermaPACE® Syst" U.S Market International Market * Diabetic Foot Ulcers - $4B+ market size. * Globally there are 382 million people living with diabetes and it is expected to reach 592 million by 2035, an increase of 55%. * dermaPACE is CE Marked and currently marketed by
Slide 13: The dermaPACE System: Treating Diabetic Foot Ulcers
The dermaPACE® System Treating Diabetic Foot Ulcers ® xx) Robust closure with Non-invasive, convenient, Mechanism of action Cost-effective May be used as an adjunct extremely low recurrence and safe (MOA) allows : therapy rates Increased blood flow (perfusion) and improved vascularization (angiogene
Slide 14: >10 million U.S. Market Strategy
>10 millon U.S. Market Strategy Pressure ! wes HSS SSS SSS SSS SS SS SSS = ! 45 1 Million 1 Expand ALU ! . di ti a | a ete eel indications Million 1 to drive increase in DT Oe I usage 3.3 Million I | 19 en | 7 TT : Million | | | | OFU i | | | ; ! ! : www 100 300 800 1600 2,200 10,000 2019 2020 2021
Slide 15: Growth Strategy
Growth Strategy Seek relationships with qualified partners and JV/licensing agreements * Address advanced wound care market - large and growing ¥ Domestic rollout of 2,000 placements; 500,000 treatments (with increasing indication) an greater than $100 million in revenue in 5 years Y International p
Slide 16: Business Model Transformation
Business Model Transformation Transform from a product company to a provider of comprehensive value propositions and solutions that address the wound care patient pathway Current Business Model Future Business Model Competitive Strategy }» Portfolio of value-added Therapy line dermaPACE® device woun
Slide 17: Global Clinical Studies
Global Clinical Studies Action Sites Q1 Q2 Q3 Q4 Qi Q2 Q3 4 Pharmacoeconomic 2019 020 DFU2 12 New AWC - VLU 12+ | i - Pressure Ulcer 12+ - ALU 12+ Mechanism of Action - Dr. Siemionow 1 Vascularization/Perfusion/Dosing - Domestic/US 3 - Global 3 Surgical Incisions/Cosmetic - Domestic/US 1
Slide 18: Intellectual Property (IP) Organic Growth
Ur US Apps) Fore US Patents Foreign P: Intellectual Property (IP) Organic Growth 2006 m2012 = 201) 8 Appl(s) TOTAL 2006 2012 2018 US Patents 14 18 Foreign Patents 10 9 lUs Appl(s) 11 9 [Foreign Appl(s) 2 10 [TOTAL 37 46 62 Percentage 24% Orthopedics, Orthopedics, Arthritis, Arthritis, Ischemia, | Is
Slide 19: Device Sales — Historical and 2019 Projection
ot evice Sales — Historical and 2019 Projection a 140 120 120 100 80 60 45 47 40 20 16 10 6 9 0 = Loma I | | 2012 2013 2014 2015 2016 2018 2019 projection SANUWAVE’
Slide 20: Non-Medical Markets
Non-Medical Markets Addressable opportunities covered by Patents Energy Production Water = Advanced Fracking = Fracking Water Cleaning = Improved / Enhanced Oil = Industrial Water Cleaning Extraction Recovery = Drinking Water Cleaning Food Industry Industrial Biofilms = Preservation * Biofilm Destru
Slide 21: Industry Valuations and Comparison
Wound Care Company Name Ticker Symbol Market Cap (as of 3/1/19) | Smith and Nephew NYSE: SNN $16.5B Industry : ‘ Integra Life Sciences Holding Corp. NASDAQ: IART $4.7B Valuations Convatec Group Plc LSE: CTEC $2.7B and . Vericel Corporation NASDAQ: VCEL $841M Comparison Organogenesis NASDAQ: ORGO $67
Slide 22: Select Financial Information
Select Financial Information Cash and Cash Equivalents - September 30, 2018 Common Shares Outstanding Warrants Options Outstanding Notes Payable - Due December 31, 2018 (1) Due to HealthTronics, Inc. as part of original 2005 purchase price SANUWAVE
Slide 23: Management Team
Management Team Kevin Richardson II, CEO and Chairman of the Board — Joined August 2005 SS Joined the Company as chairman of the board of directors in August of 2005. Brings a broad array of financial knowledge for healthcare information technology, financial services, business services and other in
Slide 24: Why Invest in SANUWAVE
Why Invest in SANUWAVE - The dermaPACE® System received FDA Clearance on 12/28/2017 - SANUWAVE contracted with Premier Shockwave in the US as the distributor for the Veteran's Association and the Indian Health Reservation - Internationally signed 15 new countries in 2018 - Equipment Finance agreemen
Slide 25: SANUWAVE Health, Inc. contact
SANUVVAVE Healing today. Curing tomorrow. To be viewed by the world as a diverse compassionate global family that provides positive impact on life and environment, one shock at a time. OTCQB: SNWV SANUWAVE Health, Inc. 3360 Martin Farm Road, Suite 100 Suwanee, GA 30024 info@sanuwave.com +1(770) 419-